EN DE
Watch Neuromeka Co.Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Neuromeka Co.Ltd. (348340) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Neuromeka Co.Ltd. stock KRW 8,488, price KRW 13,890, that is 38.9% below the price, quality 15 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials KR

NC Neuromeka Co.Ltd. logo Thin data Nov 10, 2026

Neuromeka Co.Ltd.

348340 · KQ
Very expensive, weak quality

Our calculation puts a fair price 39% below what the stock costs today.

Expensive Growth (revenue 3y +24.8 %/yr in KRW)
Moderate debt
Revenue last quarter 18% below a year ago.
Fair value 8,488 KRW · Strongly overvalued
Quality 15/100
Loss-making · -115.9% net margin (FY2025)
Negative free cash flow
Trails peers (0/10)
Narrow moat 12/100
Thin data
Estimate
Watch Neuromeka Co.Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

121,700 KRW 7,015 KRW Fair Value 8,488 KRW Nov 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

48‑month range 7,015 KRW – 121,700 KRW · fair‑value band 6,366 KRW – 10,610 KRW · the 13,890 KRW price screens above the 8,488 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Neuromeka Co.Ltd. in your weekly email

Every Wednesday you see whether Neuromeka Co.Ltd. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neuromeka Co., Ltd. manufactures industrial robots. It builds a Robot as a Service platform business ecosystem centered on collaborative robots.

Show moreShow less

The company offers collaborative, industrial, mobile, embedded, and delta robots; smart actuators, robot controllers, accessories, teach pendants, and vision solutions, as well as robot software; standard tools; and robot platform and remote maintenance management services.

It serves the manufacturing, F&B service, and media and art applications. Neuromeka Co., Ltd. was founded in 2013 and is based in Seoul, South Korea.

Stock analysis

Neuromeka Co.Ltd. (348340) currently trades at 13,890 KRW, while our estimate is 8,488 KRW, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 6,366 KRW (bear) to 10,610 KRW (bull), the price of 13,890 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 15/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Neuromeka Co.Ltd. reported revenue of 19.0B KRW in FY2025 versus 7.4B KRW in FY2021, a compound +26.7%/yr. Reported net income was −22.0B KRW in FY2025.

Key figures

Market cap 337B KRW (≈ $253M) Micro · P/S ratio 18.6 · EPS (TTM) −1,939 KRW · Net margin −116% · Return on equity −145% · Return on assets (EBIT) −16.4% (5-year average) · Operating margin −187% · Revenue (TTM) 18.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 89% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −47% fair-value upside, at −39%, 348340 screens cheaper than that median.

Fair Value

Bear 6,366 KRW Fair Value 8,488 KRW Bull 10,610 KRW
Price 13,890 KRW · Downside -38.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 15/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 17
Debt, balance sheet and risk of trouble
Investment 39
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 30
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−25.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40.9% (2021) → −78.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

348340 screens overvalued: fair value 39% below the price. Compare with SIE →

Compare Neuromeka Co.Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Industrial Machinery · 846 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 15 · Bottom 25%
Fair Value upside −38.9% · Below median
Profitability
Return on assets −24.1% · Bottom 25%
Net margin (12 months) −115.9% · Bottom 25%
Operating margin (12 months) −186.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −17.9% · Bottom 25%
Balance sheet
Debt / equity 0.58× · Highest 25%

Valuation Multiplesvs Specialty Industrial Machinery median · lower = cheaper

P/B 24.26× · Priciest 25%
P/S (12 months) 18.56× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 27
HEALTH (low debt)71 · sector 95
DIVIDEND (yield)0 · sector 28

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Cummins Inc CMI $454.18 $359.36 −21% vs 348340
SIE SIE €271.55 €149.56 −45% vs 348340
Illinois Tool Works Inc ITW $288.05 $154.30 −46% vs 348340
Sandvik AB SAND kr 366.20 kr 194.33 −47% vs 348340
AMETEK, Inc AME $238.31 $125.74 −47% vs 348340
Parker-Hannifin Corporation PH $965.17 $492.92 −49% vs 348340
Emerson Electric Co EMR $167.54 $79.99 −52% vs 348340
Rockwell Automation, Inc ROK $397.16 $186.75 −53% vs 348340
Eaton Corporation ETN $354.22 $156.90 −56% vs 348340
GE Vernova Inc GEV $797.04 $143.50 −82% vs 348340

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neuromeka Co.Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Neuromeka Co.Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/348340

Frequently asked questions

Is Neuromeka Co.Ltd. (348340) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 8,488 KRW versus a price of 13,890 KRW, about 39% lower (overvalued).
What is the fair value of 348340?
Our estimate for Neuromeka Co.Ltd. is 8,488 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 13,890 KRW.
What is the quality score of 348340?
Neuromeka Co.Ltd. has a Quality Score of 15/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuromeka Co.Ltd. (348340)?
Our calculated price target is the estimate of 8,488 KRW (as of Nov 10, 2026). Cautious scenario 6,366 KRW, optimistic scenario 10,610 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Neuromeka Co.Ltd. stock forecast for 2026?
Our estimate puts fair value at 8,488 KRW, about 39% lower versus a price of 13,890 KRW (overvalued). Cautious scenario 6,366 KRW, optimistic scenario 10,610 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Neuromeka Co.Ltd. (348340)?
Neuromeka Co.Ltd. reported trailing-twelve-month revenue of about 18.2B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Neuromeka Co.Ltd. (348340)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuromeka Co.Ltd. it is 8,488 KRW per share (as of Nov 10, 2026), against a price of 13,890 KRW.
Is Neuromeka Co.Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 348340 trades above its calculated fair value: price 13,890 KRW, fair value 8,488 KRW, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 348340?
No. The price is what the market pays today (13,890 KRW); the fair value is what the company's own numbers justify (8,488 KRW). For Neuromeka Co.Ltd. the two are 5,402 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuromeka Co.Ltd. worth?
The market values Neuromeka Co.Ltd. at about 337B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 13,890 KRW; our models calculate a fair value of 8,488 KRW per share.
What do the bullish and bearish scenarios say about 348340?
Our models span a range for Neuromeka Co.Ltd.: cautious scenario 6,366 KRW, base 8,488 KRW, optimistic 10,610 KRW per share (as of Nov 10, 2026, price 13,890 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neuromeka Co.Ltd. (348340)?
Balance-sheet figures for Neuromeka Co.Ltd. (as of Nov 10, 2026): return on equity −145.4%, debt of 0.58 per unit of equity. They feed the Quality Score of 15/100, which measures business quality independently of the share price.
How far is 348340 from its 52-week high?
Neuromeka Co.Ltd. trades at 13,890 KRW, about 89% below its 52-week high of 121,700 KRW and 5% above the low of 13,270 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 8,488 KRW is for.
Which stocks are comparable to Neuromeka Co.Ltd.?
From the same area (Industrials) we also value SIE, GE Vernova Inc, Eaton Corporation, Parker-Hannifin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuromeka Co.Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 13,890 KRW, calculated fair value 8,488 KRW (−39%), Quality Score 15/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Neuromeka Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuromeka Co.Ltd. (348340)?
The closing price on Nov 10, 2026 was 13,890 KRW. Our estimate is 8,488 KRW, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuromeka Co.Ltd. right now?
The price sits above even our optimistic bull case (10,610 KRW). The favourable scenario is already priced in. Weak quality (15/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Neuromeka Co.Ltd.

How large is the market capitalisation of Neuromeka Co.Ltd. (348340)?
The market capitalisation of Neuromeka Co.Ltd. is 337B KRW (≈ $253M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuromeka Co.Ltd. (348340)?
The price-to-sales ratio of Neuromeka Co.Ltd. is 18.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuromeka Co.Ltd. (348340)?
Earnings per share at Neuromeka Co.Ltd. are −1,939 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neuromeka Co.Ltd. (348340)?
The net margin of Neuromeka Co.Ltd. is −116% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neuromeka Co.Ltd. (348340)?
The return on equity (ROE) of Neuromeka Co.Ltd. is −145% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuromeka Co.Ltd. (348340)?
On an EBIT basis the return on assets of Neuromeka Co.Ltd. is −16.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuromeka Co.Ltd. (348340)?
The operating margin of Neuromeka Co.Ltd. is −187% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neuromeka Co.Ltd. (348340)?
Revenue at Neuromeka Co.Ltd. is growing −17.9% versus a year earlier (3y avg +24.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Neuromeka Co.Ltd. (348340) generate?
The free cash flow of Neuromeka Co.Ltd. is −14.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Neuromeka Co.Ltd. (348340) carry?
The net debt of Neuromeka Co.Ltd. is 35.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Neuromeka Co.Ltd. in the live analysis

One click puts Neuromeka Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.